Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 9;45(3):443–456. doi: 10.1007/s10928-018-9574-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 3 — Model prediction of time-based changes in the drug–drug interaction (DDI) magnitude of amlodipine and ritonavir (RTV) over multiple days after amlodipine [2.5 mg once daily (QD)] + RTV (100 mg QD) co-dosing for 14 days (Day 15–Day 28), followed by continuation of amlodipine (2.5 mg QD) alone. This was preceded by amlodipine (2.5 mg QD) dosing for 14 days. The area under the plasma-concentration time curve from time 0 to 24 h (AUC₂₄) ratio (orange line) and maximum plasma concentration (C_max) ratio (blue line) of amlodipine were estimated with respect to steady-state (Day 14) values as reference. (RTV start indicates starting of co-administration of RTV; RTV stop indicates RTV stoppage) (Color figure online)